Ernexa Therapeutics Inc.
ERNA
$0.29
$0.001.55%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 68.38% | 59.18% | -82.71% | -101.29% | -105.55% |
| Total Depreciation and Amortization | -83.94% | -87.23% | -69.63% | -27.22% | 45.86% |
| Total Amortization of Deferred Charges | -- | 29.68% | 255.16% | 543.58% | 1,635.64% |
| Total Other Non-Cash Items | -71.17% | -70.43% | 1,394.69% | 1,266.14% | 1,118.91% |
| Change in Net Operating Assets | 97.42% | -1,685.00% | -334.24% | -895.63% | 6.71% |
| Cash from Operations | 55.69% | 44.47% | 12.53% | 21.83% | 22.40% |
| Capital Expenditure | 89.97% | 94.33% | 94.85% | -123.33% | -1,842.11% |
| Sale of Property, Plant, and Equipment | -- | -100.00% | -100.00% | -100.00% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 89.86% | 94.27% | 94.79% | -131.03% | -1,821.05% |
| Total Debt Issued | -57.48% | -84.57% | -68.38% | -68.38% | -70.60% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 336.15% | -- | -- | 256.56% | 255.31% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | 100.00% | 50.00% | 50.00% |
| Other Financing Activities | -- | -22.73% | 52.63% | 45.02% | 32.67% |
| Cash from Financing | 15.16% | -36.55% | -31.39% | -60.26% | -62.19% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 101.56% | 72.23% | -415.89% | -2,495.37% | -156.81% |